Diabetes Program

HSCI scientists advance Type 1 diabetes therapy by protecting cells from immune attack and stress The stem cell-based approach to treating Type 1 diabetes (T1D) is successfully being tested in the clinic, using a transplant of stem cell-derived beta cells...

Douglas Melton, Co-Director of the Harvard Stem Cell Institute (HSCI), has received a financial grant from His Highness Sheikh Mohamed bin Zayed Al Nahyan, Crown Prince of Abu Dhabi. The grant will bolster HSCI research focusing on accelerating gene...

In the pancreas, insulin-producing beta cells are clustered with other hormone-producing endocrine cells and surrounded by pancreatic exocrine cells that secrete digestive enzymes. Harvard Stem Cell Institute (HSCI) researchers at the Joslin Diabetes...

C ALL FOR P ROPOSALS 2022 HSCI DIABETES PROGRAM PILOT GRANTS 'Targeted cargo delivery to pancreatic islet cells' AWARD AMOUNT Up to $100,000 per year per lab for up to two years POSTED DATE December 6, 2021 DEADLINE FOR APPLICATION January 28, 2022...

C ALL FOR P ROPOSALS 2022 HSCI DIABETES PROGRAM PILOT GRANTS 'Learning from cancer immunology to cure autoimmune diabetes' AWARD AMOUNT Up to $100,000 per year per lab for up to two years POSTED DATE December 6, 2021 DEADLINE FOR APPLICATION January 28...

Promising early results show that longstanding Harvard Stem Cell Institute (HSCI) research may have paved the way for a breakthrough treatment of Type 1 diabetes. Utilizing research from the Melton Lab, Vertex Pharmaceuticals has developed VX-880, an...

A Harvard Stem Cell Institute (HSCI) led collaboration developed a new macroencapsulation device (MED) that protects the insulin-producing cells of the pancreas and enhances their survival with improved nutrient supply. More than 40 million people...

The JDRF Center of Excellence in New England will accelerate beta cell replacement therapy Harvard Stem Cell Institute (HSCI) co-director Douglas Melton, Ph.D., will lead a new multi-institutional center funded by JDRF to advance type 1 diabetes research...

HSCI scientists show that engineered “5-module CAR” T cells target harmful T cells responsible for type 1 diabetes Researchers have engineered a specialized type of T cell that can specifically target and eliminate harmful T cells, particularly the...